Mitomycin, doxorubicin, and vinblastine as second-line chemotherapy in patients with advanced breast cancer.
Thirty-seven patients with disseminated breast cancer refractory to previous therapy were treated with a combination of mitomycin, doxorubicin, and vinblastine (MAV). One complete and eight partial responses were achieved, with an overall response rate of 24.3%. The median duration of response was 5+ months. The MAV regimen had generally moderate but acceptable toxicity. This study indicates that the MAV combination is no better than doxorubicin given as a single agent.
R
R
Borovik
R
R
Epelbaum
Y
Y
Cohen
E
E
Robinson
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D004317:Doxorubicin / Q000008:administration & dosage / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008875:Middle Aged; D008937:Mitomycins / Q000008:administration & dosage; D009362:Neoplasm Metastasis; D014747:Vinblastine / Q000008:administration & dosage
D000970:Antineoplastic Agents; D008937:Mitomycins; D014747:Vinblastine; D004317:Doxorubicin